Plomestane
Plomestane is an orally active second-generation steroidal aromatase inhibitor that, as an enzyme-activated pseudosubstrate, is converted via NADPH-dependent catalysis into a reactive intermediate, which covalently binds to aromatase to produce irreversible inhibition, thereby persistently suppressing peripheral aromatase activity. Plomestane can be used for the study of hormone-dependent breast cancer.
연구목적의 판매만을 진행합니다. 환자를 대상으로 한 판매는 하지 않습니다.
- CAS No.: 77016-85-4
- 화학식: C21H26O2
- 분자량:310.44
-
보관:
Please store the product under the recommended conditions in the Certificate of Analysis.
Biological Activity
제품 설명
In Vitro
Plomestane (5 nM; up to 40 min preincubation) is a high-affinity, irreversible, active-site-directed mechanism-based inactivator of human placental aromatase, with a Ki (inact.) of 3.2 nM[2].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only. Further protocols information, click here.
In Vivo
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
Chemical Information
-
CAS No. 77016-85-4
-
분자량 310.44
-
화학식 C21H26O2
-
SMILES
C(C#C)[C@@]12[C@@]3([C@]([C@]4([C@](C)(CC3)C(=O)CC4)[H])(CCC1=CC(=O)CC2)[H])[H]
-
선적
Room temperature in continental US; may vary elsewhere.
-
보관
Please store the product under the recommended conditions in the Certificate of Analysis.
Protocol
-
Research Protocol for Endocrine Diseases
Endocrine diseases often arise from disrupted hormone production, hormone signaling, or target-tissue responsiveness; for diabetes-focused endocrine disease models, insulin signaling regulates glucose uptake, hepatic glucose output, lipid metabolism, and β-cell compensation. Type 2 diabetes develops through interacting defects in insulin resistance, β-cell dysfunction, adipose inflammation, hepatic glucose overproduction, altered incretin signaling, and ectopic lipid metabolism. A major unresolved question is whether endocrine dysfunction is driven primarily by target-tissue insulin resistance, intrinsic β-cell failure, immune/inflammatory stress, or combined multi-organ failure that differs by disease stage.
-
Breast Cancer Modeling
Breast cancer is a heterogeneous cancer, and it has been distinguished into four subtypes: luminal A, luminal B, HER2-positive and basal-like. Molecular mutations, epigenetic alterations, hormone exposure and immune microenvironment are related to the progression of breast cancer.
순도&문서
References
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)